Combined Bilateral Salpingo-oophorectomy and Cesarean Delivery in BRCA1/2 Alteration Carriers: A Case Series

被引:1
|
作者
Barker, Victoria E. [1 ,2 ]
Vlachodimitropoulou, Evangelia [1 ,2 ]
O'Brien, Patrick [1 ,2 ]
Iskaros, Joseph [1 ,2 ]
Rosenthal, Adam N. [1 ,2 ,3 ]
机构
[1] Univ Coll London Hosp, Natl Hlth Serv Fdn Trust, London, England
[2] UCL, Univ Coll London Elizabeth Garrett Anderson Inst W, Dept Womens Canc, London, England
[3] Univ Coll London Hosp NHS Fdn Trust, London, England
关键词
BREAST-CANCER; OVARIAN; RISK; WOMEN;
D O I
10.1097/AOG.0000000000005423
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
BACKGROUND: The cumulative lifetime risk of ovarian cancer is 16-68% and 11-30% in female BRCA1 and BRCA2 gene alteration carriers, respectively. Risk-reducing bilateral salpingo-oophorectomy (RRSO) is the only proven way to reduce ovarian cancer mortality. We report a series of patients who underwent risk-reducing surgery at the time of planned obstetric-indicated cesarean delivery.CASES: This is a case series of four women carrying a pathogenic germline BRCA1 or BRCA2 gene alteration who underwent RRSO at the time of cesarean delivery between March 1, 2018, and March 31, 2022. All women were referred during pregnancy to the University College London Hospitals Familial Cancer Clinic for consideration of RRSO at the time of obstetric-indicated cesarean delivery. Women were considered eligible for RRSO if they had a proven pathogenic germline alteration, would have completed childbearing after the cesarean delivery, and were older than age 35 or 40 years with BRCA1 or BRCA2 alterations, respectively. Operating time, blood loss, transfusion requirements, length of hospital stay, complications, and ability to breastfeed were assessed and, where possible, compared with the institutional means for similar patients who underwent cesarean delivery only, to determine whether RRSO was associated with increased morbidity. Women were contacted 11-59 months postprocedure to assess satisfaction. The mean blood loss was 687 mL (range 400-1,000 mL), mean operating time was 68 minutes, mean length of hospital stay was 3 days, and mean change in hemoglobin was -1 g/dL. No patient required a transfusion, had internal organ damage, returned to the operating room, or was readmitted. One of two women with intact breast tissue successfully breastfed, and the other chose to bottle feed. The mean contemporaneous institutional blood loss for cesarean delivery was not significantly different at 681 mL for singleton pregnancies and 872 mL for twin pregnancies. All four women reported a high level of satisfaction with the combined procedure.CONCLUSION: Our results show that RRSO can be performed at the time of cesarean delivery with high patient satisfaction. This approach can be offered to appropriately counseled individuals, with the benefit of avoiding the need for two separate procedures, with potentially reduced patient morbidity and health care costs.
引用
收藏
页码:1500 / 1503
页数:4
相关论文
共 50 条
  • [31] Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers:: A cost-effectiveness analysis
    Norum, Jan
    Hagen, Anne Irene
    Maehle, Louise
    Apold, Jaran
    Burn, John
    Moller, Pal
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (07) : 963 - 971
  • [32] Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy
    Powell, C. B.
    Swisher, E. M.
    Cass, I.
    McLennan, J.
    Norquist, B.
    Garcia, R. L.
    Lester, J.
    Karlan, B. Y.
    Chen, L.
    GYNECOLOGIC ONCOLOGY, 2013, 129 (02) : 364 - 371
  • [33] Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis
    Wang, Yizi
    Song, Zixuan
    Zhang, Shitai
    Wang, Xiaoying
    Li, Peiwen
    EJSO, 2022, 48 (06): : 1209 - 1216
  • [34] Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction
    Heemskerk-Gerritsen, B. A. M.
    Seynaeve, C.
    van Asperen, C. J.
    Ausems, M. G. E. M.
    Collee, J. M.
    van Doorn, H. C.
    Garcia, E. B. Gomez
    Kets, C. M.
    van Leeuwen, F. E.
    Meijers-Heijboer, H. E. J.
    Mourits, M. J. E.
    van Os, T. A. M.
    Vasen, H. F. A.
    Verhoef, S.
    Rookus, M. A.
    Hooning, M. J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (05):
  • [35] Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy
    Kang, Ok-Ju
    Lee, Shin-Wha
    Kim, Ju-Hyun
    Park, Jeong-Yeol
    Suh, Dae-Shik
    Kim, Dae-Yeon
    Kim, Jong-Hyeok
    Kim, Yong-Man
    Kim, Young-Tak
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (11) : 1743 - 1749
  • [36] Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis
    Marchetti, C.
    De Felice, F.
    Boccia, S.
    Sassu, C.
    Di Donato, V.
    Perniola, G.
    Palaia, I.
    Monti, M.
    Muzii, L.
    Tombolini, V.
    Panici, P. Benedetti
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 132 : 111 - 115
  • [37] Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation
    Abay, Merve
    Ozgen, Levent
    Yalcin, Yakup
    Ozerkan, Kemal
    JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2023, 52 (08)
  • [38] Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study
    Perri, Tamar
    Levin, Gabriel
    Naor-Revel, Shani
    Eliassi-Revivo, Perry
    Lifshitz, Dror
    Friedman, Eitan
    Korach, Jacob
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2022, 157 (02) : 431 - 436
  • [39] Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy
    Menkiszak, Janusz
    Chudecka-Glaz, Anita
    Cymbaluk-Ploska, Aneta
    Celewicz, Aleksander
    Kojs, Zbigniew
    Szajda, Mariusz
    Swiniarska, Maria
    Bedner, Ryszard
    Jurczak, Anna
    Celewicz, Marta
    Cieszynska, Monika
    Lubinski, Jan
    Gronwald, Jacek
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2019, 17 (1)
  • [40] Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers
    Biglia, N.
    Mariani, L.
    Ponzone, R.
    Sismondi, P.
    MATURITAS, 2008, 60 (02) : 71 - 77